SGLT2 inhibitors improve survival over DPP4i in patients with cirrhosis and diabetes: Study
Patients with cirrhosis needing additional pharmacotherapy for diabetes beyond metformin experience increased survival with SGLT2i in relation to DPP4i.
USA: SGLT2 inhibitors versus DPP4 inhibitors may improve survival in cirrhosis patients who require additional pharmacotherapy for diabetes beyond metformin, reveal results from a recent study in the journal Diabetes, Obesity and Metabolism.
Sodium-glucose cotransporter 2 inhibitors may have favorable metabolic and neurohumoral effects in chronic liver disease patients. However, studies examining SGLT2 inhibitors in this population are limited only to patients with non-alcoholic fatty liver disease (NAFLD) and have focused on surrogate biomarkers. Considering this, Saad Saffo, Yale School of Medicine, New Haven, Connecticut, and colleagues aimed to evaluate if SGLT2i can reduce the risk of death and ascites over a period of 36 months in patients with diabetes and cirrhosis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.